PMID- 26877155
OWN - NLM
STAT- MEDLINE
DCOM- 20161214
LR  - 20211203
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 6
DP  - 2016 Feb 15
TI  - Clinical Relevance of Liver Kinase B1(LKB1) Protein and Gene Expression in Breast 
      Cancer.
PG  - 21374
LID - 10.1038/srep21374 [doi]
LID - 21374
AB  - Liver kinase B1 (LKB1) is a tumor suppressor, and its loss might lead to 
      activation of the mammalian target of rapamycin (mTOR) and tumorigenesis. This 
      study aimed to determine the clinical relevance of LKB1 gene and protein 
      expression in breast cancer patients. LKB1 protein expression was evaluated using 
      immunohistochemistry in tumors from early breast cancer patients in two Taiwanese 
      medical centers. Data on LKB1 gene expression were obtained from the Molecular 
      Taxonomy of Breast Cancer International Consortium (METABRIC) data set. The 
      correlations between LKB1 expression, clinicopathologic factors, and patient 
      outcome were analyzed. LKB1 expression was significantly associated with estrogen 
      receptor (ER) expression in 2 of the 4 cohorts, but not with other 
      clinicopathologic factors. LKB1 expression was not a predictor for relapse-free 
      survival, overall survival (OS), or breast cancer-specific survival. In a 
      subgroup analysis of the two Taiwanese cohorts, high LKB1 protein expression was 
      predictive of high OS in human epidermal growth factor receptor 2 (HER2)-positive 
      breast cancer patients (P = 0.013). Our study results indicate that LKB1 
      expression is not prognostic in the whole population of breast cancer patients, 
      but it is a potential predictor of OS in the subset of HER2-positive patients.
FAU - Chen, I-Chun
AU  - Chen IC
AD  - Department of Oncology, National Taiwan University Hospital.
AD  - Graduate Institute of Oncology, National Taiwan University.
FAU - Chang, Yuan-Ching
AU  - Chang YC
AD  - Department of Surgery, Mackay Memorial Hospital.
FAU - Lu, Yen-Shen
AU  - Lu YS
AD  - Department of Oncology, National Taiwan University Hospital.
AD  - Department of Internal Medicine, National Taiwan University Hospital.
FAU - Chung, Kuei-Pin
AU  - Chung KP
AD  - Departent of Laboratory Medicine, National Taiwan University Hospital.
FAU - Huang, Chiun-Sheng
AU  - Huang CS
AD  - Department of Surgery, National Taiwan University Hospital.
FAU - Lu, Tzu-Pin
AU  - Lu TP
AD  - Department of Public Health, National Taiwan University.
FAU - Kuo, Wen-Hung
AU  - Kuo WH
AD  - Department of Surgery, National Taiwan University Hospital.
FAU - Wang, Ming-Yang
AU  - Wang MY
AD  - Department of Surgery, National Taiwan University Hospital.
FAU - Kuo, Kuan-Ting
AU  - Kuo KT
AD  - Department of Pathology, National Taiwan University Hospital.
FAU - Wu, Pei-Fang
AU  - Wu PF
AD  - Department of Oncology, National Taiwan University Hospital.
AD  - Department of Medical Research, National Taiwan University Hospital.
FAU - Hsueh, Tsu-Hsin
AU  - Hsueh TH
AD  - Department of Oncology, National Taiwan University Hospital.
FAU - Shen, Chen-Yang
AU  - Shen CY
AD  - Graduate Institute of Life Sciences, National Defense Medical Center, Taipei.
AD  - Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
AD  - College of Public Health, China Medical University, Taichung, Taiwan.
FAU - Lin, Ching-Hung
AU  - Lin CH
AD  - Department of Oncology, National Taiwan University Hospital.
AD  - Department of Internal Medicine, National Taiwan University Hospital.
AD  - Oncology Center, National Taiwan University Hospital Hsin-Chu Branch.
FAU - Cheng, Ann-Lii
AU  - Cheng AL
AD  - Department of Oncology, National Taiwan University Hospital.
AD  - Graduate Institute of Oncology, National Taiwan University.
AD  - Department of Internal Medicine, National Taiwan University Hospital.
LA  - eng
GR  - Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160215
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (STK11 protein, human)
RN  - EC 2.7.11.3 (AMP-Activated Protein Kinase Kinases)
SB  - IM
MH  - AMP-Activated Protein Kinase Kinases
MH  - Adult
MH  - Aged
MH  - Breast Neoplasms/*genetics/pathology
MH  - Disease-Free Survival
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*genetics/pathology
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Protein Serine-Threonine Kinases/*biosynthesis/genetics
MH  - Receptor, ErbB-2/genetics
PMC - PMC4753425
EDAT- 2016/02/16 06:00
MHDA- 2016/12/15 06:00
PMCR- 2016/02/15
CRDT- 2016/02/16 06:00
PHST- 2015/09/21 00:00 [received]
PHST- 2016/01/21 00:00 [accepted]
PHST- 2016/02/16 06:00 [entrez]
PHST- 2016/02/16 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
PHST- 2016/02/15 00:00 [pmc-release]
AID - srep21374 [pii]
AID - 10.1038/srep21374 [doi]
PST - epublish
SO  - Sci Rep. 2016 Feb 15;6:21374. doi: 10.1038/srep21374.